

PATENT
Attorney Docket No.: SMART1240

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Bing Zhu, *et al.* Art Unit: 1647
Application No.: 09/927,110 Examiner: L. Spector
Filing Date: August 10, 2001 Conf. No. 3840
Title: METHOD FOR INHIBITING INFLAMMATION IN IMMUNE
PRIVILEGED SITES USING FAS LIGAND FRAGMENTS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL SHEET

Sir:

Transmitted herewith for the above-identified application, please find:

- (1) An Information Disclosure Statement (2 pages);
- (2) A Form PTO-1449 (3 pages);
- (3) Twenty-One (21) references;
- (4) Check No. 573843 in the amount of \$180.00; and
- (5) Return postcard.

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, February 3, 2005 in an envelope addressed to: Mail Stop Amendment: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Stephanie Sharrett

Name of Person Mailing Paper

Stephanie Sharrett February 3, 2005

Signature


In re Application of:
Bing Zhu, *et al.*
Application No.: 09/927,110
Filing Date: August 10, 2001
Page 2

PATENT
Attorney Docket No.: SMART1240

This Information Disclosure Statement as it is being filed prior to the receipt of a final office action or a Notice of Allowance for the above-referenced application. Applicants enclosed Check No. 573843 in the amount of \$180.00 for the fee and do not believe any other fees are due. However, if any other fee is required, authorization is hereby given to charge Deposit Account No. 07-1896. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: February 3, 2005



Lisa A. Haile, J.D., Ph.D.

Reg. No.: 38,347

Telephone: (858) 677-1456

Facsimile: (858) 677-1465

USPTO CUSTOMER NUMBER 28213
DLA PIPER RUDNICK GRAY CARY US LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92121-2133



PATENT
Attorney Docket No.: SMART1240

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Bing Zhu, <i>et al.</i>	Art Unit:	1647
Application No.:	09/927,110	Examiner:	L. Spector
Filing Date:	August 10, 2001	Conf. No.	3840
Title:	METHOD FOR INHIBITING INFLAMMATION IN IMMUNE PRIVILEGED SITES USING FAS LIGAND FRAGMENTS		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §1.97, enclosed is Form PTO-1449 which lists the references relating to the above-identified application. A copy of each reference is also enclosed for your convenience.

It is respectfully requested that these references be considered in the examination of this application and their consideration be made of written record in the application file.

02/05/2005 KURLOBE1 00000010 09927110

01 FC:1006

160.00 CP

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, February 3, 2005 in an envelope addressed to: Mail Stop Amendment: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Stephanie Sharrett

Name of Person Mailing Paper

Stephanie Sharrett February 3, 2005

Signature

In re Application of:

Bing Zhu, *et al.*

Application No.: 09/927,110

Filing Date: August 10, 2001

Page 2


PATENT

Attorney Docket No.: SMART1240

Applicants submit a Check No. 573843 in the amount of \$180.00 for the fee due in connection with the filing of this Information Disclosure Statement. This Information Disclosure Statement is being filed prior to receipt of a Final Office Action or the Notice of Allowance for the above-referenced application. Applicants do not believe any others fees are due, however, if any other fee is required, authorization is hereby given to charge Deposit Account No. 07-1896.

Respectfully submitted,

Date: February 3, 2005



Lisa A. Haile, J.D., Ph.D.

Reg. No.: 38,347

Telephone: (858) 677-1456

Facsimile: (858) 677-1465

USPTO CUSTOMER NUMBER 28213

DLA PIPER RUDNICK GRAY CARY US LLP

4365 Executive Drive, Suite 1100

San Diego, CA 92121-2133



PTO/SB/08B (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

3

Complete if Known

Application Number	09/927,110
Filing Date	August 10, 2001
First Named Inventor	ZHU, Bing
Art Unit	1647
Examiner Name	Lorraine Spector
Attorney Docket Number	SMART 1240

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Vaux DL, "Immunology. Ways around rejection" Nature 1995;377(6550):576-7	
	C2	Vaux DL, "Immunology. Ways around rejection" Nature 1998;394(6689):133	
	C3	Allison J, Georgiou HM, Strasser A, Vaux DL, "Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts" Proc Natl Acad Sci U S A 1997;94(8):3943-7	
	C4	Green DR, Ware CF, "Fas-ligand: privilege and peril" Proc Natl Acad Sci U S A 1997;94(12):5986-90	
	C5	Renshaw SA, Timmons SJ, Eaton V, Usher LR, Akil M, Bingle CD, Whyte MK, "Inflammatory neutrophils retain susceptibility to apoptosis mediated via the Fas death receptor" J Leukoc Biol 2000;67(5):662-8	
	C6	Miyawaki T, Uehara T, Nibu R, Tsuji T, Yachie A, Yonehara S, Taniguchi N, "Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood" J Immunol 1992;149(11):3753-8	
	C7	Owen-Schaub LB, Yonehara S, Crump WL, 3rd, Grimm EA, "DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement" Cell Immunol 1992;140(1):197-205	
	C8	Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F, Lynch DH, "Fas ligand mediates activation-induced cell death in human T lymphocytes" J Exp Med 1995;181(1):71-7	
	C9	Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG, Baekkeskov S, "Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction" Nat Med 1997;3(7):738-43	
	C10	Takeuchi T, Ueki T, Nishimatsu H, Kajiwarra T, Ishida T, Jishage K, Ueda O, Suzuki H, Li B, Moriyama N and others, "Accelerated rejection of Fas ligand-expressing heart grafts" J Immunol 1999;162(1):518-22	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	09/927,110
Filing Date	August 10, 2001
First Named Inventor	ZHU, Bing
Art Unit	1647
Examiner Name	Lorraine Spector
Attorney Docket Number	SMART 1240

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C11	Ottonello L, Tortolina G, Amelotti M, Dallegri F, "Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes" J Immunol 1999;162(6):3601-6	
	C12	Alderson MR, Armitage RJ, Maraskovsky E, Tough TW, Roux E, Schooley K, Ramsdell F, Lynch DH, "Fas transduces activation signals in normal human T lymphocytes" J Exp Med 1993;178(6):2231-5	
	C13	Rescigno M, Piguat V, Valzasina B, Lens S, Zubler R, French L, Kindler V, Tschopp J, Ricciardi-Castagnoli P, "Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory responses" J Exp Med 2000;192(11):1661-8	
	C14	Malipiero U, Frei K, Spanaus KS, Agresti C, Lassmann H, Hahne M, Tschopp J, Eugster HP, Fontana A, "Myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis is chronic/relapsing in perforin knockout mice, but monophasic in Fas- and Fas ligand-deficient lpr and gld mice" Eur J Immunol 1997;27(12):3151-60	
	C15	Sabelko KA, Kelly KA, Nahm MH, Cross AH, Russell JH, "Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system" J Immunol 1997;159(7):3096-9	
	C16	Waldner H, Sobel RA, Howard E, Kuchroo VK, "Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis" J Immunol 1997;159(7):3100-3	
	C17	Suarez-Pinzon W, Sorensen O, Bleackley RC, Elliott JF, Rajotte RV, Rabinovitch A, "Beta-cell destruction in NOD mice correlates with Fas (CD95) expression on beta-cells and proinflammatory cytokine expression in islets" Diabetes 1999;48(1):21-8	
	C18	Tang H, Chen K, Wei Y, Sharp GC, McKee L, Braley-Mullen H, "Apoptosis of thyrocytes and effector cells during induction and resolution of granulomatous experimental autoimmune thyroiditis" Int Immunol 2000;12(12):1629-39	


Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

3

Complete if Known

Application Number	09/927,110
Filing Date	August 10, 2001
First Named Inventor	ZHU, Bing
Art Unit	1647
Examiner Name	Lorraine Spector
Attorney Docket Number	SMART 1240

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C19	Tanaka M, Itai T, Adachi M, Nagata S, "Downregulation of Fas ligand by shedding" Nat Med 1998;4(1):31-6	
	C20	Suda T, Tanaka M, Miwa K, Nagata S, "Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand" J Immunol 1996;157(9):3918-24	
	C21	Hohlbaum AM, Moe S, Marshak-Rothstein A, "Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival" J Exp Med 2000;191(7):1209-20	
	C22		
	C23		
	C24		
	C25		
	C26		
	C27		
	C28		
	C29		
	C30		
	C31		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.